Improving Gene Replacement for Alpha-1 Antitrypsin Deficiency

Optimized Gene Replacement for AAT deficiency and Modeling of Clinical Outcomes in small and large animal models

['FUNDING_P01'] · UNIV OF MASSACHUSETTS MED SCH WORCESTER · NIH-11146479

This research is working to create better gene therapy to help people with Alpha-1 antitrypsin deficiency, a genetic condition that can harm the lungs.

Quick facts

Phase['FUNDING_P01']
Study typeNih_funding
SexAll
SponsorUNIV OF MASSACHUSETTS MED SCH WORCESTER (nih funded)
Locations1 site (WORCESTER, UNITED STATES)
Trial IDNIH-11146479 on ClinicalTrials.gov

What this research studies

Alpha-1 antitrypsin deficiency (AATD) is a genetic condition where the body doesn't make enough of a protective protein, leading to lung damage and emphysema. Current treatments involve regular infusions, but it's unclear if these truly improve lung function. Our team is developing new gene replacement methods to restore the missing protein, using advanced techniques like rAAV gene therapy and CRISPR technology. We are testing these optimized approaches in animal models to understand how they might work in people.

Who could benefit from this research

Good fit: This research is relevant for patients diagnosed with Alpha-1 antitrypsin deficiency, particularly those with the common E242K (PI*Z) mutation.

Not a fit: Patients without Alpha-1 antitrypsin deficiency or those with different underlying conditions would not directly benefit from this specific gene therapy approach.

Why it matters

Potential benefit: If successful, this gene replacement approach could offer a more effective and lasting way to protect the lungs of patients with Alpha-1 antitrypsin deficiency.

How similar studies have performed: Previous gene therapy efforts by this lab have shown sustained protein levels in patients, though not yet reaching target levels, indicating a foundation for this optimized approach.

Where this research is happening

WORCESTER, UNITED STATES

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.

View on NIH RePORTER →

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.